NUVB
Nuvation Bio Inc.About NUVB
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.
Company
- Headquarters
- New York, NY
- Employees
- 305 (2026)
- Listed
- Feb 10, 2021
- Exchange
- NYSE
- Website
- nuvationbio.com
- SEC industry
- Pharmaceutical Preparations
- Cylvex sector
- Health Care · Pharmaceuticals
Pharmaceuticals
- Market cap #100 of 430
- P/B #60 of 396
Ranked highest first among stocks Cylvex covers.
- LLYEli Lilly and Company$1.26T+0.60%
- JNJJohnson & Johnson$665.3B+3.83%
- ABBVAbbVie Inc$520.9B+3.07%
- MRKMerck & Co Inc$370.9B+3.91%
- NVSNovartis AG$311.6B+3.60%
Financial summary
Related companies
About
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.
From company filings and market data · Not investment advice
Price data
From daily bars
Financials
Consensus estimates
The information provided is for educational purposes only and does not constitute investment advice. Past performance does not guarantee future results.